BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 30176357)

  • 1. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia.
    Jung Y; Song KH; Cho Je; Kim HS; Kim NH; Kim TS; Choe PG; Chung JY; Park WB; Bang JH; Kim ES; Park KU; Park SW; Kim HB; Kim NJ; Oh MD
    Int J Antimicrob Agents; 2014 Feb; 43(2):179-83. PubMed ID: 24315788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A stewardship program's retrospective evaluation of vancomycin AUC24/MIC and time to microbiological clearance in patients with methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Gawronski KM; Goff DA; Brown J; Khadem TM; Bauer KA
    Clin Ther; 2013 Jun; 35(6):772-9. PubMed ID: 23795575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
    Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
    J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of an AUC
    Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
    Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
    Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Ghosh N; Chavada R; Maley M; van Hal SJ
    Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vancomycin 24-Hour Area under the Curve/Minimum Bactericidal Concentration Ratio as a Novel Predictor of Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Britt NS; Patel N; Horvat RT; Steed ME
    Antimicrob Agents Chemother; 2016 May; 60(5):3070-5. PubMed ID: 26953202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimizing outcomes using vancomycin therapeutic drug monitoring in patients with MRSA bacteremia: trough concentrations or area under the curve?
    Johnston MM; Huang V; Hall ST; Buckley MS; Bikin D; Barletta JF
    Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115442. PubMed ID: 34192639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
    Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
    Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
    [No Abstract]   [Full Text] [Related]  

  • 12. Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.
    Zasowski EJ; Murray KP; Trinh TD; Finch NA; Pogue JM; Mynatt RP; Rybak MJ
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The dosing and monitoring of vancomycin: what is the best way forward?
    Drennan PG; Begg EJ; Gardiner SJ; Kirkpatrick CMJ; Chambers ST
    Int J Antimicrob Agents; 2019 Apr; 53(4):401-407. PubMed ID: 30599240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest® macromethod among patients with MRSA bloodstream infections: a pilot study.
    Martirosov DM; Bidell MR; Pai MP; Scheetz MH; Rosenkranz SL; Faragon C; Malik M; Mendes RE; Jones RN; McNutt LA; Lodise TP
    BMC Infect Dis; 2017 Aug; 17(1):534. PubMed ID: 28764660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
    Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
    Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Vancomycin Use Through 2-Point AUC-Based Therapeutic Drug Monitoring in Pediatric Patients.
    Suchartlikitwong P; Anugulruengkitt S; Wacharachaisurapol N; Jantarabenjakul W; Sophonphan J; Theerawit T; Chatsuwan T; Wattanavijitkul T; Puthanakit T
    J Clin Pharmacol; 2019 Dec; 59(12):1597-1605. PubMed ID: 31342543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
    Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
    Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
    Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
    J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis.
    Steinmetz T; Eliakim-Raz N; Goldberg E; Leibovici L; Yahav D
    Clin Microbiol Infect; 2015 Jul; 21(7):665-73. PubMed ID: 25887712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients.
    Makmor-Bakry M; Ahmat A; Shamsuddin A; Lau CL; Ramli R
    Anaesthesiol Intensive Ther; 2019; 51(3):218-223. PubMed ID: 31434472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.